First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient 
with EGFR Exon 20 Insertion Mutantion

With the continuous innovation of genomics, proteomics and molecular biological detection technology, the treatment of non-small cell lung cancer (NSCLC) has changed from traditional chemotherapy to immunotherapy and targeted therapy. Among them, molecular tumor markers targeting tyrosine kinase pat...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Zhengguo LI, Ting WEI, Duo ZENG, Li ZHAO, Jianting ZHANG, Laixiu CHEN
Format:	Artigo
Sprache:	Chinês
Veröffentlicht:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2024-03-01
Schriftenreihe:	Chinese Journal of Lung Cancer
Schlagworte:	lung neoplasms furmonertinib mesylate epidermal growth factor receptor exon 20 insertion mutation
Online-Zugang:	http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.11
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!